Autoantibodies in biological agent naive patients with psoriatic arthritis

Annals of the Rheumatic Diseases

Volumn 64, Issue 5, 2005, Pages 770-772

  Johnson, S R ^a   Schentag, C T ^a   Gladman, D D ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DNA ANTIBODY; DOUBLE STRANDED DNA; LA ANTIBODY; RHEUMATOID FACTOR; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; DISEASE ACTIVITY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN CELL; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; AUTOANTIBODIES; AUTOANTIGENS; BIOLOGICAL RESPONSE MODIFIERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REFERENCE VALUES; RIBONUCLEOPROTEINS; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 17644393195     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2004.031286     Document Type: Article

References (15)

1. Gladman DD, Brockbank J. Psoriatic arthritis. Expert Opin Investig Drugs 2000;9:1511-22.
2. Lambert JR, Scott G, Wright V. Psoriatic arthritis and anti-nuclear factor. Br J Dermatol 1977;96:11-14.
3. Calzavara PG, Cattaneo R, Franceschini F, Tosoni C, Martinelli M, Carlino A. Antinuclear antibodies in psoriatic arthritis and its subgroups. Acta Derm Venereol Suppl (Stockh) 1989;146:31-2.
4. Sonnichsen N, Apostologg G. [On the evidence of antinuclear factors in various forms of psoriasis.] Arch Klin Exp Dermatol, 1966;227:247-9.
5. Panayi GS. Immunology of psoriasis and psoriatic arthritis. Baillieres Clin Rheumatol 1994;8:419-27.
6. Feletar M, Brockbank JE, Schentag CT, Lapp V, Gladman DD. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004;63:156-61.
7. Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA) - an analysis of 220 patients. Q J Med 1987;62:127-41.
8. Tan EM, Feltkamp TE, Smolen JS, Butcher B, Dawkins R, Fritzler MJ, et al. Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum 1997;40:1601-11.
9. Craig WY, Ledue TB, Johnson AM, Ritchie RF. The distribution of antinuclear antibody liters in "normal" children and adults. J Rheumatol 1999;26:914-19.
10. Leonard DG, O'Duffy JD, Rogers RS. Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978;53:511-18.
11. Mustakallio KK, Lassus A, Rasanen JA. Antinuclear factors in psoriatic arthritis. Acta Pathol Microbiol Scand 1967;69:615-16.
12. Rosenberg JN, Johnson GD, Holborow EJ. Antinuclear antibodies in ankylosing spondylitis, psoriatic arthritis, and psoriasis. Ann Rheum Dis 1979;38:526-8.
13. Zachariae H, Zachariae E. Antinuclear factors, the antihuman globulin consumption test, and Wassermann reaction in psoriatic arthritis. Acta Rheumatol Scand 1969;15:62-6.
14. Sonnichsen N. Immunologic studies on the nosologic picture of psoriatic arthritis. Allergie und Asthma 1969;15:124-8.
15. Sonnichsen N, Kluge K, Miemiec E. [The clinical picture and nosology of psoriasis arthropathica.] Z Gesamte Inn Med, 1971;26:742-4.